Gresham John, Mansfield Candi L, Brush John E
Eastern Virginia Medical School, Norfolk, VA, 23502, USA.
J Invasive Cardiol. 2002 Nov;14(11):665-9.
Short- and long-term comparative follow-up studies of patients receiving primary angioplasty or thrombolytic therapy for acute myocardial infarction show higher 30-day survival, and sustained benefits in mortality, reinfarction and ejection fraction in patients treated with primary angioplasty. Long-term benefits of primary angioplasty on cardiac function performed in community hospitals without surgical back-up have not been fully assessed.
Sixty-one patients who underwent primary angioplasty were compared with patients receiving thrombolytic therapy who were matched for age, gender and location of acute myocardial infarction. Clinical information, reviewed through August 2000, was provided by retrospective analysis of healthcare databases and office and hospital charts. Mortality data were confirmed by the social security death index.
Of the original 61 primary angioplasty patients, two died during initial hospitalization. Of the 59 surviving patients, fifty-four (92%) had complete follow-up averaging 57 months. Of the original 61 thrombolytic therapy patients, three died during initial hospitalization. Of the 58 surviving patients, fifty-two (90%) had complete follow-up averaging 46 months. At follow-up, averaging 57 months, ejection fraction was significantly higher in the primary angioplasty group, as compared with the thrombolytic therapy group (51.4% versus 45.8%, respectively; p = 0.038). There was no statistical difference between the two groups regarding reinfarction, revascularization at > or = 6 months after the initial presentation or cardiac death.
Primary angioplasty performed in a community hospital without surgical back-up results in improved cardiac function when compared to thrombolytic therapy. These results are similar to those reported from large tertiary centers with on-site surgical back-up, and provide an explanation for the improved long-term outcome that is observed in patients with acute myocardial infarction treated with primary angioplasty.
对接受急性心肌梗死直接血管成形术或溶栓治疗的患者进行的短期和长期比较随访研究表明,直接血管成形术治疗的患者30天生存率更高,且在死亡率、再梗死率和射血分数方面具有持续的益处。在没有外科支持的社区医院进行的直接血管成形术对心脏功能的长期益处尚未得到充分评估。
将61例行直接血管成形术的患者与年龄、性别和急性心肌梗死部位相匹配的接受溶栓治疗的患者进行比较。通过对医疗保健数据库以及办公室和医院病历的回顾性分析,提供截至2000年8月的临床信息。死亡率数据经社会保障死亡指数确认。
在最初的61例直接血管成形术患者中,2例在初次住院期间死亡。在59例存活患者中,54例(92%)完成了平均57个月的随访。在最初的61例溶栓治疗患者中,3例在初次住院期间死亡。在58例存活患者中,52例(90%)完成了平均46个月的随访。随访平均57个月时,直接血管成形术组的射血分数显著高于溶栓治疗组(分别为51.4%和45.8%;p = 0.038)。两组在再梗死、初次发病后≥6个月的血管重建或心源性死亡方面无统计学差异。
与溶栓治疗相比,在没有外科支持的社区医院进行直接血管成形术可改善心脏功能。这些结果与大型三级中心报告的结果相似,这些中心有现场外科支持,并为接受直接血管成形术治疗的急性心肌梗死患者观察到的长期预后改善提供了解释。